A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Canakinumab (Primary) ; Capmatinib (Primary) ; LAG 525 (Primary) ; Spartalizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PLATforM
- Sponsors Novartis Pharmaceuticals
- 15 Jan 2019 Planned primary completion date changed from 9 Sep 2020 to 29 Jun 2020.
- 13 Dec 2018 Planned End Date changed from 29 Mar 2021 to 28 Mar 2022.
- 26 Nov 2018 Planned End Date changed from 8 Sep 2021 to 29 Mar 2021.